Overview

Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients

Status:
Terminated
Trial end date:
2011-08-01
Target enrollment:
0
Participant gender:
All
Summary
To assess the safety and efficacy of PMI-150 (Intranasal Ketamine) as an analgesic for the treatment of breakthrough pain in cancer patients.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Hospira, Inc.
Hospira, now a wholly owned subsidiary of Pfizer
Treatments:
Ketamine
Criteria
Inclusion Criteria:

- at least 18 years of age

- Patients requiring around-the-clock opioids for pain due to cancer and with a history
of experiencing episodes of breakthrough pain

Exclusion Criteria:

- under 18 years

- non-cancer pain

- allergy to ketamine